Monopar Therapeutics (NASDAQ:MNPR) Given New $85.00 Price Target at Chardan Capital

Monopar Therapeutics (NASDAQ:MNPR) had its price target hoisted by Chardan Capital from $60.00 to $85.00 in a research note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also commented on MNPR. Lake Street Capital assumed coverage on shares of Monopar Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $106.00 price target on the stock. Oppenheimer assumed coverage on Monopar Therapeutics in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $77.00 target price on the stock. Raymond James Financial assumed coverage on Monopar Therapeutics in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $80.00 target price on the stock. BTIG Research boosted their price target on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday. Finally, HC Wainwright started coverage on Monopar Therapeutics in a research report on Tuesday, August 26th. They issued a “buy” rating and a $70.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $82.33.

Monopar Therapeutics Stock Down 1.0%

Shares of MNPR stock opened at $76.63 on Thursday. The stock has a market cap of $472.81 million, a P/E ratio of -23.01 and a beta of 1.20. Monopar Therapeutics has a fifty-two week low of $4.50 and a fifty-two week high of $79.80. The business has a fifty day simple moving average of $44.46 and a 200-day simple moving average of $39.43.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.12. On average, sell-side analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Tactic Pharma Llc sold 550,229 shares of Monopar Therapeutics stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider owned 272,026 shares of the company’s stock, valued at $17,303,573.86. The trade was a 66.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the company’s stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the completion of the transaction, the director owned 11,486 shares of the company’s stock, valued at $459,440. The trade was a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 592,733 shares of company stock worth $36,700,227 over the last ninety days. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics in the second quarter valued at approximately $34,000. AlphaQuest LLC acquired a new position in shares of Monopar Therapeutics in the 1st quarter valued at $44,000. JPMorgan Chase & Co. grew its stake in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Monopar Therapeutics during the 2nd quarter worth $80,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Monopar Therapeutics in the 2nd quarter worth about $104,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.